A Short-Term Surge Narrative Created by a Major M&A Catalyst and Explosive Trading Volume

Reviewing Prediction vs. Actual Result

The predicted return of -2.5% was significantly surpassed, with the actual result reaching 102.8%, resulting in an OVERHIT designation. At the time of entry, the RSI(14) was at 76.0, indicating an overbought condition, and the stock experienced a significant adjustment that day. We anticipated a range-bound movement between the 20-day low support level ($0.34) and the high resistance level ($0.54), along with a conservative stop-loss trigger at the -2.5% level. However, the impact of a major catalyst, specifically a $150 million merger and the stock's surge ('Werewolf Therapeutics stock soars 120% on Ambros merger deal'), allowed it to break through the anticipated resistance level of $0.54, leading to a much larger increase. Our failure to interpret the trading volume, which surged to 81.94 times the 20-day average, more aggressively and our judgment that it would only move within a conservative band contributed to the discrepancy with the actual results.

What to Watch in the Next Analysis

In the event of a strong thematic catalyst such as a large-scale M&A or corporate merger, rather than responding conservatively too early by only observing technical overheating (RSI 76) or short-term correction trends, I will apply flexibility in the next trades by keeping the sustainability of momentum, accompanied by a surge in trading volume (over 80 times the 20-day average), open and resetting the profit-taking target.